Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Hello and thank you for standing by. My name is Regina and will ...

Astellas said in a results update this morning that Padcev (enfortumab vedotin) will now bring in JPY 400 to 500 billion ($2.7 to $3.4 billion) on the back of the EV-302 study showing that the ...

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the fastest ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer, these ...